Article Versions Notes

Tasker S, Wight O’Rourke A, Suyundikov A, Jackson Booth P-G, Bart S, Krishnan V, Zhang J, Anderson KJ, Georges B, Roberts MS. Safety and Immunogenicity of a Novel Intranasal Influenza Vaccine (NasoVAX): A Phase 2 Randomized, Controlled Trial. Vaccines. 2021; 9(3):224. https://doi.org/10.3390/vaccines9030224

Tasker, Sybil, Anna Wight O’Rourke, Anvar Suyundikov, Peta-Gay Jackson Booth, Stephan Bart, Vyjayanthi Krishnan, Jianfeng Zhang, Katie J. Anderson, Bertrand Georges, and M. Scot Roberts. 2021. "Safety and Immunogenicity of a Novel Intranasal Influenza Vaccine (NasoVAX): A Phase 2 Randomized, Controlled Trial" Vaccines 9, no. 3: 224. https://doi.org/10.3390/vaccines9030224

Tasker, S., Wight O’Rourke, A., Suyundikov, A., Jackson Booth, P.-G., Bart, S., Krishnan, V., Zhang, J., Anderson, K. J., Georges, B., & Roberts, M. S. (2021). Safety and Immunogenicity of a Novel Intranasal Influenza Vaccine (NasoVAX): A Phase 2 Randomized, Controlled Trial. Vaccines, 9(3), 224. https://doi.org/10.3390/vaccines9030224